The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma.
Anthony J. Chalmers
Research Funding - AstraZeneca
Alan Jackson
No relevant relationships to disclose
Helen Swaisland
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
William Stewart
No relevant relationships to disclose
Sarah E. R. Halford
No relevant relationships to disclose
L Rhoda Molife
Research Funding - AstraZeneca
Darren R Hargrave
No relevant relationships to disclose
Alex McCormick
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca